Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT06090331 | 89Zr-DFO-girentuximab Expanded Access Program (EAP) | no longer available | — | — | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT03756311 | Expanded Access to NanoPac | no longer available | — | — | NanOlogy, LLCINDUSTRY | 0 | Jan 23, 2026 | clinicaltrials |
| NCT03523338 | An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer | no longer available | — | — | Aragon Pharmaceuticals, Inc.INDUSTRY | 3 | Dec 10, 2025 | clinicaltrials |
| NCT04681248 | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | no longer available | — | — | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03493165 | Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020) | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT05002465 | Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer | no longer available | — | — | Dana MathewsOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05415228 | Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer | no longer available | — | — | Morand Piert, MDOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT04854369 | 68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)(Firefly) | no longer available | — | — | Tulane UniversityOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT04825652 | 177Lu-PSMA-617 Managed Access Program for mCRPC Patients | no longer available | — | — | Advanced Accelerator ApplicationsINDUSTRY | 0 | Jan 13, 2023 | clinicaltrials |
| NCT03123211 | Expanded Access to Veliparib | no longer available | — | — | AbbVieINDUSTRY | 0 | May 24, 2022 | clinicaltrials |
| NCT03501940 | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | no longer available | — | — | Andrei IagaruOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT04800068 | Expanded Access [Ga-68] PSMA-11 PET Imaging | no longer available | — | — | Mayo ClinicOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03801278 | An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer(FPA144) | no longer available | — | — | Five Prime Therapeutics, Inc.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT02826395 | C11 Sodium Acetate PET/CT Imaging of PCa | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02531672 | Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography | no longer available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT01834209 | A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 7, 2018 | clinicaltrials |
| NCT01777061 | Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan | no longer available | — | — | Wendell Yap, MDOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03005262 | MLN8237 for a Subject With Adenocarcinoma of the Prostate | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | Apr 4, 2018 | clinicaltrials |
| NCT01956253 | Single Subject Neratinib in Bladder Cancer (NRR) | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
| NCT01516762 | Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | no longer available | — | — | BayerINDUSTRY | 1 | Jul 14, 2014 | clinicaltrials |
| NCT01473043 | Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment | no longer available | — | — | PfizerINDUSTRY | 2 | May 30, 2014 | clinicaltrials |
| NCT00655252 | Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 19, 2011 | clinicaltrials |
| NCT00636259 | Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer | no longer available | — | — | AstraZenecaINDUSTRY | 0 | Jun 11, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Jul 2, 2026source: clinicaltrials